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Abstract Being recalled for further diagnostic proce-
dures after an abnormal screening mammogram (ASM) can
evoke a high state anxiety with lowered quality of life
(QoL). We examined whether these adverse psychological
consequences are found in all women with benign breast
disease (BBD) or are particular to women referred after
ASM. In addition, the influence of the anxiety as a per-
sonality characteristic (trait anxiety) was studied. Between
September 2002 and February 2010 we performed a pro-
spective longitudinal study in six Dutch hospitals. Women
referred after ASM or with a palpable lump in the breast
(PL), who were subsequently diagnosed with BBD, were
included. Before diagnosis (at referral) and during follow-
up, questionnaires were completed examining trait anxiety
(at referral), state anxiety, depressive symptoms (at refer-
ral, one, three and 6 months after diagnosis), and QoL
(at referral and 12 months). Women referred after ASM
(N = 363) were compared with women with PL
(N = 401). A similar state anxiety score was found in both
groups, but a lower psychological QoL score at 12 months
was seen in the ASM group. In women with not-high trait
anxiety those in the ASM group were more anxious with
more depressive symptoms at referral, and reported
impaired psychological QoL at referral and at 12 months
compared with the PL group. No differences were found
between ASM and PL in women with high trait anxiety, but
this group scored unfavorably on anxiety, depressive
symptoms and QoL compared with women with not-high
trait anxiety. ASM evokes more anxiety and depressive
symptoms and lowered QoL compared with women
referred with PL, especially in women who are not prone to
anxiety. Women should be fully informed properly about
the risks and benefits of breast cancer screening programs.
We recommend identifying women at risk of reduced QoL
using a psychometric test.
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Introduction
Breast cancer (BC) is the most common cancer among
women. In the western world, one in eight women is at risk
of developing BC [1, 2]. However, the majority of women
visiting the surgical outpatient clinic with breast problems,
such as a palpable lump (PL) or an abnormal screening
mammogram (ASM), are diagnosed with benign breast
disease (BBD) [3]. During the investigation of breast
symptoms, women experience increased anxiety and dis-
tress [4–6]. Even after a diagnosis of BBD is made, these
symptoms persist in a proportion of women [4]. Women
with BBD diagnosed after an ASM report ongoing anxiety
[7–9] with lowered quality of life (QoL) [10, 11]. In
chronically anxious women (i.e., with high trait anxiety),
these psychological effects are heightened [6, 10, 12]. Trait
anxiety refers to relatively stable individual differences in
anxiety proneness [13].
Thus, it is important to evaluate women diagnosed with
BBD as the lack of reassurance after the diagnostic work-
up and adverse psychological consequences may result in
lowered QoL. Although these effects on women with BBD
have been previously studied, a comparison between
women referred after an ASM or with PL has not been
performed before. This comparison is important in the
context of the ongoing discussions on whether the advan-
tages of a BC screening program still outweigh the disad-
vantages (such as the false-positive findings) [14, 15].
Therefore, we examined whether all women with BBD
(ASM and PL) experience similar levels of anxiety (state
anxiety), depressive symptoms, and changes in QoL during
and in the year following the diagnostic work-up. Women
attending breast screening usually have no palpable lump
in the breast and so are not expecting an ASM. We
hypothesized that these women are more alarmed by being
recalled for further diagnostic procedures and experience
more adverse psychological effects compared with women
with a PL. Based on previous studies, we also analyzed the
influence of the personality characteristic trait anxiety [10,
16].
In this prospective, longitudinal study comparing ASM
with PL, women completed the first set of question-




Women referred after an ASM or with a PL were eligible
for participating in this study. The study was conducted
between September 2002 and February 2010 in six Dutch
hospitals. The Medical Ethical Committee of the primary
research hospital, i.e., St. Elisabeth Hospital, Tilburg,
approved the study protocol. This study was part of a larger
study analyzing the impact of personality and QoL on
morbidity, mortality, and health care consumption in breast
disease. Women with recurrent BBD or BC, inability to
read and write in Dutch, or (previous) psychiatric illness
were excluded. When women were invited to participate in
the study and completed the first set of questionnaires, the
diagnosis was unknown. All participants gave written
informed consent.
Since 1990, BC screening is offered every 2 years to
women in the age between 50 and 75 years in the Neth-
erlands. Every year one million women receive an invita-
tion for BC screening mammogram. The overall attendance
rate is 80 % [17]. Two-view mammography was used at
initial BC screening. All women with an ASM were
referred to a dedicated outpatient breast clinic.
Questionnaires
Questionnaires were completed at referral (before diagno-
sis was known), and one, three, six, and 12 months after
diagnosis. The questionnaires assessed personality at
referral (STAI-trait), experienced momentary anxiety
(STAI-state) and depressive symptoms (CES-D) at referral
until 6 months, and QoL (WHOQOL-bref) at referral and
12 months after diagnosis.
The state-and-trait-anxiety-inventory (STAI) measures
two types of anxiety: trait and state. Trait anxiety refers to
the tendency to respond to situations perceived as threat-
ening with a rise in anxiety intensity. State anxiety refers to
the amount of stress being experienced at the specific
moment the measurement is made [13, 18]. In this study,
the short 6-item state version and 10-item trait version of
the STAI were used [19, 20]. High trait anxiety (HTA) was
defined as a score greater than 22. The reliability and
validity of the short versions are considered good [19, 20].
The Center for Epidemiological Studies-depression
scale (CES-D) was used to assess depressive symptoms. It
measures both the presence and the degree of depressive
symptoms. The psychometric properties are good [21, 22].
The World Health Organization Quality of Life assess-
ment instrument-Bref (WHOQOL-Bref) is a short version
of the WHOQOL-100 [23, 24]. The WHOQOL-Bref con-
sists of questions assessing QoL within four domains
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(physical health, psychological health, social relationships,
and environment) and a general evaluative facet (overall
QoL and general health). The psychometric properties of
the WHOQOL-Bref have been demonstrated to be good in
women with benign breast disease [3].
Women were also asked to complete a questionnaire
concerning demographic characteristics. The medical data
concerning patient and mammography characteristics were
obtained from the medical records.
Statistics
Women who did not complete all questionnaires during
follow up, were excluded from further analysis and con-
sidered as drop-outs. Chi-square tests and independent
t tests were used to compare women in the non drop-out and
drop-out groups, and in the ASM or PL groups with regard
to demographic (age, children, marital status, paid work,
and educational level) and personality (trait anxiety) char-
acteristics at baseline. Differences in demographic charac-
teristics were used as covariates in the subsequent analysis.
A repeated measures general linear model was used to
examine scores on state anxiety and depressive symptoms
(at referral until 6 months), and QoL (at referral and
12 months) across time (i) in the two groups ASM or PL,
and (ii) in women with HTA or not-high score on trait
anxiety (NHTA) in ASM or PL group. A P value \0.05
was considered statistical significant. All analyses were
performed with the Statistical Package for Social Sciences
(SPSS version 18.0).
Results
During the study period, 1145 women were diagnosed with
BBD. During follow-up, 381 women did not complete all
questionnaires, and were excluded from further analysis.
Women in the drop-out group were less educated
(P = 0.016) and scored higher on trait anxiety (P \ 0.001)
compared with the group that remained in the study. There
was no difference concerning referral after ASM or PL.
In total, 764 women were analyzed at referral, 363
women in the ASM group, and 401 in the PL group. At
referral, significant differences were observed concerning
demographics between the two groups (Table 1). Women
in the ASM group were older (P \ 0.001), more often had
children (P = 0.009), and less often had paid work
(P \ 0.001). There was no difference between the two
groups concerning trait anxiety at referral.
At referral, the mean scores for state anxiety were
comparable in the ASM and PL groups (P = 0.074;
Table 1). In both groups, the state anxiety scores signifi-
cantly decreased after 1 month compared with the scores at
referral (P \ 0.001; Table 1). Concerning depressive
symptoms, a higher mean score was found in ASM com-
pared with PL at referral (P = 0.007), in both groups
scores significantly decreased at 1 month compared with
the scores at referral (P \ 0.001; Table 1). After 1 month,
no differences between the two groups were found. From 1
month follow-up scores on state anxiety and depressive
symptoms remained similar until 6 months in both groups
(Table 1). Concerning the scores on QoL, there were no
differences between the ASM and the PL groups at referral.
At 12 months, women in the ASM group scored lower on
psychological QoL (P = 0.022) compared with the PL
group.
In the subanalysis, women were divided in four groups
based on referral after ASM or with PL and their scores on
trait anxiety (HTA or NHTA).
High trait anxiety
Women with HTA (N = 160) scored higher at all mea-
surement moments on state anxiety, depressive symptoms,
and lower on QoL compared with women with NHTA
(P \ 0.001; Table 2). Within the group with HTA, women
in the PL and ASM groups scored similar on state anxiety,
depressive symptoms, and QoL (Table 2; Figs. 1, 2). In
both groups, scores on depressive symptoms decreased
significantly at 1 month compared with scores at referral
(P \ 0.001). The only difference was a higher score on
psychological QoL at referral in the ASM group
(P = 0.029).
Not-high trait anxiety
In women with NHTA (N = 604), higher scores on state
anxiety at referral were found in the ASM group compared
with the PL group (P = 0.047). During follow-up, these
scores significantly diminished after 1 month compared
with the scores at referral in both groups (P \ 0.001;
Table 2; Fig. 1), and the scores remained similar until
6 months compared with 1 month, without differences
between groups. Scores on depressive symptoms were
higher in ASM at referral compared with PL (P \ 0.001;
Table 2; Fig. 2). In both groups, scores after 1 month
remained similar during follow-up. Concerning QoL,
women in the ASM group scored lower on psychological
QoL at referral (P = 0.022) and at 12 months (P = 0.005)
compared with the PL group.
Discussion
The discussion concerning the disadvantages of the BC
screening program, such as false-positive findings, is still
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ongoing and contributing to the screening controversy [14,
15]. The adverse psychological consequences after a false-
positive screening mammogram are already described
before [7–11, 16]. However, to our knowledge, a com-
parison between women with BBD referred after ASM or
PL has not yet been performed. We hypothesized that
women referred after ASM experience more adverse psy-
chological effects compared with women referred with PL.
As previously found, the negative effects in our study
were strengthened by the personality characteristic trait
anxiety, i.e., women with HTA scored unfavorably on state
anxiety, depressive symptoms, and QoL, compared with
women not prone to anxiety [6, 10, 12]. Before diagnosis
was known, all women scored higher on state anxiety and
depressive symptoms compared with 1 month after diag-
nosis, when women were relieved that BC was not found.
Table 1 Demographic and
psychological characteristics
comparing two groups: women
with benign breast disease
referred with an abnormal
screening mammogram (ASM)
or with a palpable lump in
breast (PL)
SD standard deviation. P value
\0.05 considered significant
and presented in bold
a Scores diminished
significantly at 6 months
compared with scores at referral
ASM (n = 363) PL (n = 401) P value
Demographics
Mean age (SD) 56.2 (6.8) 46.5 (10.9) <0.001
Partner n (%) 308 (85) 348 (87) 0.315
Children n (%) 315 (88) 322 (81) 0.009
Education low/moderate n (%) 290 (80) 306 (76) 0.053
Paid work n (%) 194 (54) 289 (72) <0.001
Personality
High score on trait anxiety n (%) 75 (21) 85 (21) 0.856
Psychological factors mean scores (SD)
State anxiety at referral 12.9 (4.0) 12.4 (3.8) 0.074
State anxiety 6 months 10.4 (3.4)a 10.4 (3.5)a 0.988
Depressive symptoms at referral 8.8 (8.2) 7.2 (7.6) 0.007
Depressive symptoms 6 months 6.5 (7.0)a 6.0 (7.1)a 0.407
General quality of life at referral 7.9 (1.4) 7.9 (1.4) 0.732
General quality of life 12 months 7.7 (1.4) 8.0 (1.4) 0.385
Table 2 Scores at referral and during follow up on state anxiety,
depressive symptoms, and general quality of life (QoL) comparing
four groups based on referral after abnormal screening program
(ASM) or with palpable lump in breast (PL) and high trait anxiety
(HTA) or not-high trait anxiety (NHTA)
Mean scores
(SD)
ASM (n = 75) PL (n = 85) P value
HTAa At referral 6 months At referral 6 months
State anxiety 15.7 (3.4) 13.1 (3.6) 15.5 (3.5) 13.2 (3.6) NS
Depressive
symptoms
15.8 (9.3) 11.4 (9.3)b 14.7 (9.6) 12.3 (8.8)b NS
At referral 12 months At referral 12 months
General QoL 6.9 (1.4) 6.9 (1.6) 6.7 (1.5) 6.7 (1.3) NS
ASM n = 288 PL n = 316 P value
NHTAa At referral 6 months At referral 6 months
State anxiety 12.2 (3.9) 9.7 (3.0)b 11.6 (3.4) 9.7 (3.1)b R 0.047
Depressive
symptoms
7.0 (6.8) 5.3 (5.6) 5.2 (5.4) 4.4 (5.4) R \ 0.001
At referral 12 months At referral 12 months
General QoL 8.1 (1.4) 8.0 (1.3) 8.2 (1.2) 8.3 (1.2) NS
P value \0.05 considered significant. SD standard deviation, NS not significant, R significant difference at referral comparing ASM and PL
a All values in the HTA groups are significant different compared with NHTA groups (P \ 0.001)
b Scores significantly changed at 6 months compared with scores at referral
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In addition, we have found that within women not prone to
anxiety, those in the ASM group were more anxious before
diagnosis was known and experienced more depressive
symptoms at referral compared with all women with PL. In
addition, those women reported impaired psychological
QoL at referral and 1 year after diagnosis compared with
PL. In chronically anxious women higher scores on
depressive symptoms at referral were found compared with
1 month after diagnosis, regardless of being referred after
an ASM or with a PL.
Thus, the negative impact of a false-positive screening
mammogram on anxiety, depressive symptoms, and QoL is
especially found in women who do not have a high pro-
pensity for anxiety, confirming our previous findings [16].
These effects cannot be considered as a normal response to
the diagnostic work up for breast disease, because not
every woman responds similar to the threat of possibly
having BC. The fact that women not prone to anxiety are
affected more implies that being recalled for further diag-
nostic procedures after an ASM is a serious psychological
problem, especially because the adverse effects persist at
least 1 year after the diagnostic process showed by the
lowered QoL.
The present findings contribute to the ongoing screening
controversy: are the advantages of the BC screening pro-
gram still in balance with the disadvantages? Recent data
has suggested that screening has little detectable impact on
BC mortality [25]. In addition, several publications have
discussed the benefits and harms of the BC screening
program [14, 15, 26–31]. Currently the decision to partic-
ipate in the BC screening program is based upon infor-
mation in favor of screening. The risk for possible adverse
psychological consequences, overdiagnosis and overtreat-
ment are not mentioned in the provided information [14,
28–30, 32, 33].
Conclusions
This study reveals that women recalled after an ASM
experience higher state anxiety and depressive symptoms
at referral with lowered QoL 1 year after diagnosis, com-
pared with women with a PL, especially women not prone
to anxiety. Therefore, we recommend that women should
be informed properly concerning the benefits and risks of
the BC screening program, in particular mentioning the
adverse psychological consequences after a false-positive
screening mammogram. In addition, at intake women
should be offered a psychometric test to identify those who
are at risk for impaired QoL.
Ethical standards
The study was approved by the Medical Ethical Com-
mittee.
Fig. 1 State anxiety for women with high or not-high trait anxiety
comparing ASM and PL groups at referral and during follow-up until
6 months. HTA high trait anxiety, PL palpable lump in the breast, ASM
abnormal screening mammogram, and NHTA not-high trait anxiety
Fig. 2 Depressive symptoms for women with high or not-high trait
anxiety comparing ASM and PL groups at referral and during follow-
up until 6 months. HTA high trait anxiety, PL palpable lump in the
breast, ASM abnormal screening mammogram, and NHTA not-high
trait anxiety
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